Novel HIV Treatments by Fragment-Based Drug Design and Screening
Received Date: May 30, 2023 / Published Date: Jun 27, 2023
Abstract
Recently disulfide-rich head-to-tail cyclic peptides have attracted the hobby of medicinal chemists owing to their fantastic thermal, chemical and enzymatic steadiness added about by means of their restrained structures. Here we overview present day tendencies in the subject of peptide-based prescribed drugs and describe naturally taking place cyclic disulfide-rich peptide scaffolds, discussing their pharmaceutically beautiful houses and benefits. We describe how we can utilise these secure frameworks to graft and/or engineer pharmaceutically fascinating epitopes to amplify their selectivity and bioactivity, opening up new probabilities for addressing ‘difficult’ pharmaceutical targets. The Human Immunodeficiency Virus (HIV) is a complicated retrovirus that regularly deteriorates the immune gadget of contaminated patients, finally inflicting death. Although antiviral capsules are no longer in a position to eradicate the HIV, they are designed to inhibit the characteristic of three necessary proteins in the virus replication process: protease, reverse transcriptase and integrase. However, due to an excessive mutation rate, this virus is succesful to advance resistance to present tablets inflicting the remedy failure.
Citation: Franklin R (2023) Novel HIV Treatments by Fragment-Based DrugDesign and Screening. J Cell Mol Pharmacol 7: 160. Doi: 10.4172/jcmp.1000160
Copyright: © 2023 Franklin R. This is an open-access article distributed underthe terms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.
Share This Article
Recommended Journals
Open Access Journals
Article Tools
Article Usage
- Total views: 397
- [From(publication date): 0-2023 - Feb 23, 2025]
- Breakdown by view type
- HTML page views: 329
- PDF downloads: 68